Skip to main content
. 2021 Oct 20;7(43):eabj3107. doi: 10.1126/sciadv.abj3107

Fig. 4. SARS-CoV-2 SApNP vaccines induce long-term lymph node follicle retention.

Fig. 4.

(A and B) S2GΔHR2-presenting I3-01v9 SApNP vaccine distribution in a lymph node 12 hours after (A) a single-dose or (B) prime-boost footpad injections (10 μg per footpad, 40 μg per mouse). A schematic illustration of SApNPs in lymph node follicles is shown. (C and D) Histological images of the S2GΔHR2 spike and S2GΔHR2-presenting E2p and I3-01v9 SApNP vaccine trafficking and retention in lymph node follicles 2 hours to 8 weeks after (C) single-dose or (D) prime-boost injections, with a scale bar of 50 μm shown for each image. (E and F) Quantification of vaccine accumulation in lymph node follicles 48 hours after (E) a single-dose or (F) prime-boost injections. In mouse immunization, soluble spike was mixed with AddaVax, E2p SApNP was mixed with AddaVax, and I3-01v9 SApNP was mixed with AP. Data were collected from more than 10 lymph node follicles (n = 3 to 4 mice per group). The data points are expressed as means ± SD. The data were analyzed using one-way ANOVA followed by Tukey’s multiple comparison post hoc test. **P < 0.01, ***P < 0.001, and ****P < 0.0001.